ATE.V - Antibe Therapeutics Inc


#1

Une de mes positions $ATE.V Antibe Therapeutics a reçue l’approbation de Santé Canada pour procéder à la phase II du développement de leur drogue ATB-346, un anti-inflammatoire NSAID sans les effets gastriques des médicaments tel l’ibuprofen. http://www.antibethera.com/2016/03/07/antibe-therapeutics-receives-approval-to-proceed-to-phase-2-clinical-trial/

La compagnie a aussi signé une entente avec Knight Therapeutics $GUD.TO pour les droits de commercialisation: http://www.antibethera.com/2015/11/16/antibe-enters-into-a-gud-product-licensing-agreement-with-knight-therapeutics/

L’ex CFO de Paladin Labs Samrira Sakhia est sur le board:
Le CEO de Knight Therapeutics Jonathan Goodman était sur le board de la compagnie et détient encore des actions dans $ATE.V et via la placement de Bloom Burton Healthcare fund.

“The world needs safer anti-inflammatory drugs, and we are pleased to have secured Antibe’s innovative portfolio for our territories. We have come to know their management team and are also pleased to provide financial support for their strategic thrust into regenerative medicine”, said Jonathan Ross Goodman, President and CEO of Knight.

Antibe a fait l’acquisition de la Compagnie Citagenix qui les supportes comme réseau de vente et distribution qui a un estimé de revenu de $10mil par année.
Les états financiers au Q4 2015 avec les revenus de Citagenix sont disponibles sur Sedar. http://www.antibethera.com/2015/10/06/antibe-therapeutics-announces-strategic-transactions/

Pipeline de drogue: http://www.antibethera.com/pipeline/

60% de actions est détenues par des insider:

Voici la charte. L’action avait été démolie en janvier 2015 suite aux résultats de la phase I qui demandait plus de validation des tests:

Selon le MD&A la compagnie veut amener leur drogue ATB-346 jusqu’à la fin de la phase II avec une sortie stratégique.

Personnellement, je trouve intéressant le network et les personnes impliqués dans cette compagnie et le progrès qu’ils ont fait depuis le résultat. Je suis long. Mes premières actions ont été acheté à $0,07 jusqu’à $0.15.

Le site web de la compagnie:
http://www.antibethera.com


La Cuisine Espace MicroCaps - Discussions ouvertes
#2

J’ai créé un nouveau sujet étant donné qu’il y beaucoup d’information dans ton post et que la compagnie semble intéressante!

J’ai toujours un peu de misère avec les compagnies qui ne sont pas profitables (ni près de le devenir). Cependant comme tu le mentionnes, avec les gens qui sont impliqués dans l’entreprise il y a de bonnes chances que ça vaille la peine de creuser un peu.


#3

Intéressant aussi de voir que Scott Curtis est maintenant VP Business Development depuis Janvier 2016. Il était analyste chez Cantor et couvrait entre autre Biosyent.

http://www.antibethera.com/about/leadership/
https://ca.linkedin.com/in/scott-curtis-0005a72b

C’est à suivre à mon avis


#4

Nouvelle présentation pour les investisseurs en date du 20 Mars 2016.

http://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20March%202016.pdf


#5

Insider buying en date du 28 et 29 mars 2016:


#6

Antibe Therapeutics Announces Appointment of the Giordano Group, Inc, a Division of Network 1 Financial Securities LLC, as US-BASED Investor Relations Consultant

http://finance.yahoo.com/news/antibe-therapeutics-announces-appointment-giordano-220000285.html

Tous les pions semblent alignés pour Antibe Therapeutics.


#7

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery


#8

Antibe Therapeutics to Present at 2016 Bloom Burton & Co. Healthcare Investor Conference

http://finance.yahoo.com/news/antibe-therapeutics-present-2016-bloom-114500905.html


#9

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

Intéressant les gros joueuts Gold sponsors incluant Sanofi et Silver Bristol Meyers. À noter que Antibe Therapeutics est Gold Sponsor


#10

Antibe Therapeutics a complété un placement privé. Certains insiders ont participé aussi.

Antibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement
http://finance.yahoo.com/news/antibe-therapeutics-raises-968-500-204500950.html

Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000
http://finance.yahoo.com/news/antibe-therapeutics-completes-final-closing-214500612.html

Voici le vidéo de la présentation de John Wallace à la “4th-International-Conference-on-The-Biology-of-Hydrogen-Sulfide” qui explique le développement de leur drug ATB-346, qui explique ce qui s’est passé à la phase I et qui est très content des résultats jusqu’à présent durant les tests cliniques de la phase II. La compagnie s’attend à avoir les résultats cliniques d’ici juillet.
http://congressbox.it/h2sconference/data/talks/20160604--02--01.-Wallace-J.-L/media/video.mp4

Soure: http://www.en.fondazione-menarini.it/Archived-News/2016/H2S-2016-4th-International-Conference-on-The-Biology-of-Hydrogen-Sulfide/Multimedia-Contents


#11

Interview avec le CEO Dan Legault sur Biotuesdays

Antibe to have Phase 2 pain data by third quarter
http://biotuesdays.com/2016/06/21/antibe-to-have-phase-2-pain-data-by-third-quarter/

Rien de nouveau comme information de mon côté mais peut-être que cela aidera certains d’entre vous à mieux comprendre la compagnie. Toujours long. Je crois que les résultats de la phase II vont faire popper le stock, il est dans une période de consolidation et “tight range trading” depuis longtemps.

Divulgation: je détiens 200000 actions.


#12

Plusieurs nouvelles durant mes vacances:

Une intéressante addition au Board, un actionnaire qui détenait déjà des actions (voir CanadianInsider pour sa position)

Antibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
JULY 19, 2016
http://www.antibethera.com/2016/07/19/antibe-therapeutics-announces-the-appointment-of-new-board-member-and-provides-update-on-phase-2-trial-of-atb-346/

Antibe Therapeutics Reports 2016 Year-End Financial and Operating Results
JULY 29, 2016
http://www.antibethera.com/2016/07/29/antibe-therapeutics-reports-2016-year-end-financial-and-operating-results/

Antibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis
AUGUST 8, 2016
http://www.antibethera.com/2016/08/08/antibe-therapeutics-announces-successful-phase-2-trial-of-atb-346-in-osteoarthritis/

Sur nouvelle de la phase 2 l’action a terminée à 0.22 pour +29% aujourd’hui sur 1.6mil de volume.

Toujours long. Je m’attend à ce que cette compagnie dépasse le 100mil de market cap.


#13

Nouvelle intéressante pour le futur de Antibe Therapeutics $ATE.V, Samira Sakhia du Board de direction a été recrutée par Knight Therapeutics $GUD.TO comme présidente. Il faut dire quelle était CFO de Paladin Labs. Beaucoup de connection entre les membres de Antibe Therapeutics et Knight Therapeutics.

A Knight is Reborn
https://ca.finance.yahoo.com/news/knight-reborn-120000832.html

Je suis aussi actionnaire de Knight Therapeutics.


#14

Antibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference
http://finance.yahoo.com/news/antibe-therapeutics-present-2016-rodman-220000752.html


#15

http://finance.yahoo.com/news/atb-346-shows-promising-results-104500576.html

ATB-346 Shows Promising Results in Experimental Melanoma

Business Wire September 22, 2016
TORONTO–(BUSINESS WIRE)–
Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, continues to demonstrate the anti-cancer potential of its lead drug, ATB-346. In a separate study earlier this year, ATB-346 was shown to be very effective in reversing colon and intestinal tumour growth in mice. Further to this study, a new publication has shown promising results in the chemoprevention and treatment of melanoma in mice. Melanoma is one of the most drug-resistant and invasive types of cancer, and both the incidence and mortality rates are increasing.

“Although we remain focused on our ongoing human studies to advance ATB-346 as a treatment for pain and inflammation, we have compelling data from studies of colon cancer and now melanoma,” commented John Wallace, Chief Scientific Officer of Antibe. “We are encouraged by these preliminary data and plan to continue this research in support of the potential advancement of ATB-346 into selected cancer indications.”
In the new publication, Dr. Angela Ianaro’s laboratory at the University of Naples (Italy), in collaboration with Dr. Wallace, examined the possibility that ATB-346 may have greater beneficial effects in terms of reducing melanoma than naproxen, the most-prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. NSAIDs have been shown to reduce tumour growth, but they also cause significant gastrointestinal bleeding. In contrast, ATB-346 has been shown to be GI-safe in animal studies.
The effects of ATB-346 were first compared to naproxen in an in vitro melanoma model, and was found to be much more effective. The investigators then implanted melanoma cells into mice, and monitored the growth of tumours. Treatment with naproxen had a modest beneficial effect, reducing tumour volume by 23% and tumour weight by 20%. In contrast, treatment with an equivalent dose of ATB-346 was 3-times more effective, reducing tumour volume by 69% and tumour weight by 61%. Mechanistic studies confirmed that ATB-346 was more effective in promoting death (apoptosis) of cancer cells.
The article was published online in the September issue of the journal “Pharmacological Research” and can be found at: www.sciencedirect.com/science/article/pii/S1043661816304467


#16

Antibe Therapeutics dans Science Mag du 16 Septembre

“The H2S-releasing compounds that have reached clinical trials reflect more down-to-earth goals. One drug, developed by Antibe Therapeutics of Toronto, Canada, pairs naproxen, a nonsteroidal anti-inflammatory drug (NSAID), with another molecule that emits H2S. Popular painkillers, NSAIDs can cause gastrointestinal (GI) problems such as bleeding. The hope, says pharmacologist John Wallace, Antibe’s founder, is that the gas will quell these side effects. “A GI-safe NSAID has great potential,” he says. In August, the company announced positive results from a phase II trial of the drug in people with knee arthritis.”


#17

Antibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics

Business Wire October 11, 2016
TORONTO–(BUSINESS WIRE)–
Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announces that its subsidiary Citagenix Inc. (“Citagenix”) is launching a strategic initiative to drive growth of product sales in the U.S. market for dental biologics. Citagenix recently hired three senior-level sales directors with a wealth of industry experience who will be responsible for managing and executing this strategy.
“We are very excited to announce the addition of these deeply experienced sales professionals to the Citagenix team as we embark on our growth strategy in the United States,” said Dan Legault, Antibe’s CEO. “This initiative strengthens Citagenix’s ability to compete and grow market share in this important market, and we expect it should contribute materially to profitability in a few quarters.”
The new sales directors collectively have 65 years of experience in selling and promoting biologics and medical devices in the United States, bringing valuable customer relationships that Citagenix can leverage immediately. In addition, this new sales team will be responsible for engaging and supporting new distributors and independent representatives in key regions across the United States. The strategic initiative will also involve additional product development efforts and enhanced marketing and systems support.
According to iData Research, the U.S. market for dental bone graft substitutes and other dental biomaterials was US$341 million in 2014, representing the largest global market for oral regenerative medicine.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives and the size of the market for dental biologics. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005583/en/


#18

Antibe Therapeutics Confirms Non-Addictive Properties for its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer
OCTOBER 17, 2016
TORONTO, CANADA — (October 17, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) is pleased to provide an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain. Recently completed pre-clinical studies have now demonstrated that ATB-352, unlike opiate drugs, does not bind to opioid receptors and therefore does not pose a risk of addiction.

Opiates, such as oxycontin and fentanyl, are among the most widely used drugs to relieve acute, severe pain, with annual sales exceeding US$7 billion. However, these drugs carry a high risk of addiction and abuse. As earlier announced, Antibe is developing ATB-352, a novel hydrogen sulfide-releasing analgesic, to address the growing need for a powerful but safe and non-addictive pain-killer.

ATB-352 reduces pain by very potently suppressing production of pain-signaling substances called “prostaglandins”. The drug is rapidly absorbed and shows a pharmacokinetic profile consistent with once-daily dosing. ATB-352 is a derivative of ketoprofen, a powerful analgesic that carries a high risk of producing gastrointestinal ulcers. However, in animal studies, ATB-352 did not cause ulcers or bleeding, even when given at high doses daily for 5 days. Small amounts of hydrogen sulfide released from ATB-352 protect the lining of the GI tract, and provide additional analgesic and anti-inflammatory effects.

John Wallace, Antibe’s Chief Scientific Officer, remarked, “ATB-352 is intended for short-term use in relieving severe pain, such as that associated with migraine, toothache, sports injuries, post-surgery, dysmenorrhea, and a variety of other conditions. Because of the intended short-term use, the development plan for ATB-352 is considerably accelerated as compared to that for a chronic-use drug, such as ATB-346, Antibe’s lead drug being developed for the treatment of arthritis.”

http://www.antibethera.com/2016/10/17/antibe-therapeutics-confirms-non-addictive-properties-for-its-second-pipeline-drug-atb-352-a-potent-non-addictive-pain-killer/


#19

Un bon résumé du positionnement stratégique pour 2017 et pour bien comprendre le pipeline dans une lettre publiée du CEO aujourd’hui.


#20

Antibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement
http://finance.yahoo.com/news/antibe-therapeutics-raises-2-4-114500128.html

“Insiders of the Corporation and their affiliates subscribed for 1,300,000 Units under the Offering for aggregate cash consideration of $195,000.”

J’aime que Antibe Therapeutics n’a pas eu besoin d’annoncer son placement privé publiquement, que le management a participé. La compagnie va utilisé l’argent pour le développement clinique de ATB-346. Les données et résultats du “placebo-controlled” devrait être disponible Q2 2017 en Avril. Je suis long!